Mobile Site ›

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 82091 :
Amyloid Protein Identification, Paraffin, LC MS/MS

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Certain diseases are caused by abnormal deposition of proteins in extracellular sites. An example is amyloid which consists of several subtypes-systemic, familial, localized, and secondary. Each subtype is caused by a different protein. Because the management of amyloidosis relies on the treatment of the underlying etiology and differs radically for different amyloid subtypes, accurate characterization of the amyloid fibrils is important. This assay identifies the proteins associated with extracellular deposits including the proteins important in typing amyloidosis: for instance, ATTR (transthyretin/prealbumin; familial amyloidosis), AA (serum amyloid A), SAA (secondary amyloidosis), and AL (immunoglobulin light chain, lambda or kappa; primary amyloidosis).

Useful For Suggests clinical disorders or settings where the test may be helpful

Identification of proteins associated with extracellular deposits, including amyloidosis


This test is appropriate for all tissue types in routinely processed paraffin- embedded biopsy specimens

Interpretation Provides information to assist in interpretation of the test results

This test will be processed as a pathology consultation. An interpretation will be provided.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

This test is not an orderable test. Order 70012 / Pathology Consultation. The consultant will determine the need for special stains.


This request will be processed as a consultation. An interpretive report will be provided.

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Vrana JA, Gamez JD, Madden BJ, et al: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114(24):4957-4959

2. Rodriguez FJ, Gamez JD, Vrana JA, et al: Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab. Invest. 2008;88(10);1024-1037

3. Picken MM: New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens 2007;16:196-203

4. Dispenzieri A, Gertz MA: The laboratory diagnosis and monitoring of amyloidosis. Communique 2002;27(9):1-10

The Amyloid Protein Identification test employs Liquid Tissue® sample preparation licensed from Expression Pathology Inc., Rockville MD, under U.S. Patent 7,473,532 and patents pending and foreign equivalents thereof.